Dianthus Therapeutics, trading under the symbol NASDAQ:DNTH, is a biopharmaceutical company focused on developing treatments for autoimmune and inflammatory diseases. Recently, Trevor Allred from Oppenheimer set a price target of $145 for DNTH, suggesting a potential upside of 79.28% from its current trading price of $80.88, as highlighted by StreetInsider.
The company's stock has seen a remarkable 13-fold increase over the past two years. This growth is partly due to the company's advancements in its experimental treatment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The announcement of this development has significantly boosted investor interest, leading to a surge in the stock price.
Currently, DNTH is priced at $80.68, reflecting a 23.74% increase, or $15.48 rise. The stock has fluctuated between $78 and $84.86 today, with the latter marking its highest price over the past year. This volatility indicates strong investor activity and interest in the company's future prospects.
Dianthus Therapeutics has a market capitalization of approximately $2.92 billion, with a trading volume of about 2.9 million shares. The stock's lowest price over the past year was $13.37, showcasing its significant growth trajectory. This growth, coupled with the recent price target set by Oppenheimer, highlights the company's potential in the biopharmaceutical sector.
